Illinois Municipal Retirement Fund Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Illinois Municipal Retirement Fund raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 9.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 195,297 shares of the medical equipment provider's stock after purchasing an additional 17,664 shares during the period. Illinois Municipal Retirement Fund owned approximately 0.09% of Hologic worth $12,063,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in HOLX. LaFleur & Godfrey LLC boosted its stake in Hologic by 2.9% during the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after purchasing an additional 3,655 shares during the last quarter. Private Advisor Group LLC boosted its stake in shares of Hologic by 7.7% in the 4th quarter. Private Advisor Group LLC now owns 17,931 shares of the medical equipment provider's stock worth $1,293,000 after buying an additional 1,278 shares during the last quarter. New York Life Investment Management LLC boosted its stake in shares of Hologic by 1.0% in the 4th quarter. New York Life Investment Management LLC now owns 35,012 shares of the medical equipment provider's stock worth $2,524,000 after buying an additional 361 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Hologic by 1.8% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 93,660 shares of the medical equipment provider's stock worth $6,752,000 after buying an additional 1,700 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in shares of Hologic by 6.3% in the 4th quarter. Oppenheimer & Co. Inc. now owns 21,225 shares of the medical equipment provider's stock worth $1,530,000 after buying an additional 1,250 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.88% of the company's stock.

Hologic Price Performance

Shares of Hologic stock traded down $0.10 during trading hours on Friday, hitting $65.01. The company's stock had a trading volume of 3,320,131 shares, compared to its average volume of 2,369,901. The business has a 50 day moving average price of $60.00 and a two-hundred day moving average price of $63.98. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The company has a market cap of $14.49 billion, a PE ratio of 27.43, a PEG ratio of 2.38 and a beta of 0.55. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company posted $1.03 EPS. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on HOLX shares. Raymond James Financial restated an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Evercore ISI dropped their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Morgan Stanley dropped their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Finally, Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of "Hold" and a consensus target price of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.